<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="Blome 2020"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<note type="doctype">ORIGINAL RESEARCH<lb/></note>

	<docTitle>
	<titlePart>Relevant Patient Benefit of Sublingual<lb/> Immunotherapy with Birch Pollen Allergen Extract<lb/> in Allergic Rhinitis: An Open, Prospective, Non-<lb/>Interventional Study<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Christine Blome . Meike Hadler . Efstrathios Karagiannis .<lb/> Julia Kisch . Christopher Neht . Nora Kressel . Matthias Augustin<lb/></docAuthor>
	</byline>

	<note type="submission">Received: February 19, 2020 /</note>

	Published online:
	<date>April 28, 2020<lb/></date>

	<note type="copyright">Ó The Author(s) 2020</note>

	ABSTRACT<lb/>
	<div type="abstract">Introduction: Sublingual<lb/> immunotherapy<lb/> (SLIT) with birch pollen extract has been shown<lb/> to be an efficacious treatment of allergic rhinitis<lb/> (AR). An as-yet unanswered question is whether<lb/> and how clinical benefit translates into patient<lb/> benefit, i.e. what benefit patients derive from<lb/> this treatment.<lb/> Methods: This 1-year, open, prospective, mul-<lb/>ticenter, non-interventional study conducted in<lb/> 75 German centers measured patient-relevant<lb/> benefit of birch pollen SLIT (Staloral Ò Birch)<lb/> using the questionnaire &apos;&apos;Patient Benefit Index<lb/> for Allergic Rhinitis (PBI-AR)&apos;&apos;. At treatment<lb/> onset, patients rated the importance of 25<lb/> treatment needs; after the first birch pollen<lb/> season on treatment, goal achievement was<lb/> evaluated. A preference-weighted benefit index<lb/> was calculated and its association with gender,<lb/> asthma, allergy status, and severity of AR<lb/> symptoms was determined.<lb/> Results: Mean age of the 291 adult patients was<lb/> 38.8 years; 58.4% were female. The most<lb/> important treatment goals were to &apos;&apos;be able to<lb/> stay outdoors without symptoms&apos;&apos; (87.3% quite<lb/> or very important), &apos;&apos;no longer have a runny or<lb/> stuffed-up nose&apos;&apos; (86.9%), and &apos;&apos;be able to<lb/> breathe through your nose more freely&apos;&apos;<lb/> (86.9%). The treatment goals with the highest<lb/> benefit ratings (referring to those patients to<lb/> whom the respective goal applied) were to<lb/> &apos;&apos;have confidence in the therapy&apos;&apos; (60.5% has<lb/> helped &apos;&apos;quite&apos;&apos; or &apos;&apos;very much&apos;&apos;), &apos;&apos;have an easily<lb/> applicable treatment&apos;&apos; (55.6%), and &apos;&apos;be able to<lb/> breathe through my nose more freely&apos;&apos; (51.7%).<lb/> The average PBI-AR global score was 2.19 (SD<lb/> 1.04) (0-4; with 4 indicating maximum benefit).<lb/> No significant differences in PBI-AR global score<lb/> or subscales were found between men and<lb/> women, poly-and monoallergic patients, or<lb/> patients with severe versus mild rhinoconjunc-<lb/>tivitis. Patients with asthma reported relevant<lb/> but lower benefit than patients without asthma.<lb/> Conclusion: After 1 year of birch pollen SLIT<lb/> treatment, patients reported considerable ben-<lb/>efit, mainly due to a reduction of physical<lb/> symptoms and treatment burden.<lb/> Digital Features To view digital features for this article<lb/> go to https://doi.org/10.6084/m9.figshare.12091017.<lb/></div>

	<byline>
	<docAuthor>C. Blome (&amp;) Á J. Kisch Á C. Neht Á N. Kressel Á<lb/> M. Augustin<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Institute for Health Services Research in<lb/> Dermatology and Nursing (IVDP), University<lb/> Medical Center Hamburg-Eppendorf (UKE),<lb/></affiliation>
	</byline>

	<address>Martinistr. 52, 20246 Hamburg, Germany<lb/></address>

	e-mail:
	<email>c.blome@uke.de<lb/></email>

	<byline>
	<docAuthor>M. Hadler<lb/> Stallergenes GmbH, Carl-Friedrich-Gauß-Straße 50,<lb/></docAuthor>
	</byline>

	<address>47475 Kamp-Lintfort, Germany<lb/> E. Karagiannis<lb/> Stallergenes Greer, 6 Rue Alexis de Tocqueville,<lb/> 92160 Antony, France<lb/></address>

	<reference>Adv Ther (2020) 37:2932-2945<lb/></reference>

	<idno>https://doi.org/10.1007/s12325-020-01345-7<lb/></idno>

	Keywords:
	<keyword>Birch<lb/> pollen;<lb/> Patient-relevant<lb/> benefit;<lb/> Patient-reported<lb/> outcomes;<lb/> Rhinoconjunctivitis;<lb/> Sublingual<lb/> immunotherapy; Treatment goals<lb/></keyword>

	Key Summary Points<lb/> Why carry out this study?<lb/>
	<div type="abstract">Allergic rhinitis has significant impact on<lb/> patient well-being.<lb/> Sublingual immunotherapy with birch<lb/> pollen extract has proven clinical benefit<lb/> in allergic rhinitis.<lb/> This study evaluates whether and how this<lb/> clinical benefit translates into patient-<lb/>reported and patient-relevant benefit<lb/> 1 year after treatment onset.<lb/> What was learned from the study?<lb/> Most patients perceived the treatment as<lb/> at least partially successful in achieving<lb/> their self-defined treatment goals, in<lb/> particular with regard to physical<lb/> symptoms and treatment burden.<lb/></div>

	<reference>Adv Ther (2020) 37:2932-2945</reference>

		</front>
	</text>
</tei>
